source
- Amylyx reports positive pivotal trial results for drug targeting post-bariatric hypoglycemiaAmylyx announced that its experimental therapy achieved statistically significant improvement in patients who experience severe hypoglycemia after bariatric surgery. The company said the pivotal t…
- Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 millionLeo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight. Under the deal, Leo Pharm…